1. Home
  2. BCDA vs JTAI Comparison

BCDA vs JTAI Comparison

Compare BCDA & JTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • JTAI
  • Stock Information
  • Founded
  • BCDA N/A
  • JTAI 2018
  • Country
  • BCDA United States
  • JTAI United States
  • Employees
  • BCDA N/A
  • JTAI N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • JTAI Blank Checks
  • Sector
  • BCDA Health Care
  • JTAI Finance
  • Exchange
  • BCDA Nasdaq
  • JTAI Nasdaq
  • Market Cap
  • BCDA 7.9M
  • JTAI 7.1M
  • IPO Year
  • BCDA N/A
  • JTAI N/A
  • Fundamental
  • Price
  • BCDA $2.54
  • JTAI $2.52
  • Analyst Decision
  • BCDA Strong Buy
  • JTAI
  • Analyst Count
  • BCDA 1
  • JTAI 0
  • Target Price
  • BCDA $25.00
  • JTAI N/A
  • AVG Volume (30 Days)
  • BCDA 54.1K
  • JTAI 161.7K
  • Earning Date
  • BCDA 03-26-2025
  • JTAI 03-31-2025
  • Dividend Yield
  • BCDA N/A
  • JTAI N/A
  • EPS Growth
  • BCDA N/A
  • JTAI N/A
  • EPS
  • BCDA N/A
  • JTAI N/A
  • Revenue
  • BCDA $71,000.00
  • JTAI $15,028,926.00
  • Revenue This Year
  • BCDA N/A
  • JTAI $21.49
  • Revenue Next Year
  • BCDA N/A
  • JTAI $10.05
  • P/E Ratio
  • BCDA N/A
  • JTAI N/A
  • Revenue Growth
  • BCDA N/A
  • JTAI 46.66
  • 52 Week Low
  • BCDA $1.63
  • JTAI $2.30
  • 52 Week High
  • BCDA $8.85
  • JTAI $315.00
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 56.72
  • JTAI 33.13
  • Support Level
  • BCDA $2.12
  • JTAI $2.30
  • Resistance Level
  • BCDA $2.73
  • JTAI $2.60
  • Average True Range (ATR)
  • BCDA 0.22
  • JTAI 0.28
  • MACD
  • BCDA 0.03
  • JTAI 0.01
  • Stochastic Oscillator
  • BCDA 58.21
  • JTAI 15.15

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About JTAI Jet.AI Inc.

Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as via Jet Token's leased and managed aircraft.

Share on Social Networks: